Your browser doesn't support javascript.
loading
Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan, Suganthi; Bortnik, Svetlana; Dragowska, Wieslawa H; Xu, Jing; Abeysundara, Namal; Leung, Amy; Go, Nancy E; DeVorkin, Lindsay; Weppler, Sherry A; Gelmon, Karen; Yapp, Donald T; Bally, Marcel B; Gorski, Sharon M.
Afiliação
  • Chittaranjan S; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Bortnik S; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Dragowska WH; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Xu J; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Abeysundara N; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Leung A; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Go NE; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • DeVorkin L; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Weppler SA; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Gelmon K; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Yapp DT; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Bally MB; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
  • Gorski SM; Authors' Affiliations: The Genome Sciences Centre; Department of Experimental Therapeutics; Medical Oncology, BC Cancer Agency; Interdisciplinary Oncology Program, Departments of Medicine and Pathology and Laboratory Medicine, Faculty of Pharmaceutical Sciences, University of British Columbia, Vanco
Clin Cancer Res ; 20(12): 3159-73, 2014 Jun 15.
Article em En | MEDLINE | ID: mdl-24721646
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autofagia / Epirubicina / Resistencia a Medicamentos Antineoplásicos / Antraciclinas / Neoplasias de Mama Triplo Negativas / Antibióticos Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autofagia / Epirubicina / Resistencia a Medicamentos Antineoplásicos / Antraciclinas / Neoplasias de Mama Triplo Negativas / Antibióticos Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article